Weed Stocks Are Blowing Up in 2021: Buy or Sell?

Canopy Growth stock and Aphria stock are off to blazing starts in 2021. With marijuana legalization looming in most U.S. states, investors are torn between buying and selling weed stocks.

| More on:
edit Jars of marijuana

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Should investors unload their weed stocks or buy more in 2021? The winds of change are blowing in the U.S., and Canadian and American cannabis producers are thrilled. In the stock market, Canopy Growth (TSX:WEED)(NYSE:CGC) and Aphria (TSX:APHA)(NASDAQ:APHA) are stunningly gaining traction.

Industry leader Canopy Growth has gained 37% in January, while Aphria’s year-to-date gain is an incredible 87%. The two companies should be the industry’s top draws this year, as they compete for market leadership across the border. Cannabis investors are hopeful a “true” marijuana boom is coming.

Solidifying leadership position

Investors’ sentiment in cannabis is soaring once more. Constellations Brands, a significant stockholder in Canopy Growth, could finally hit pay dirt. Despite Canopy’s US$37.1 million loss in Q4 fiscal 2020, the U.S. drink firm remains upbeat about the business prospects.

Constellation Brands even increased its ownership in the Canadian pot grower to 38.5%. The stake could jump to 55.8% if the beverage company exercises its warrants and senior notes. Bill Newlands, Constellation Brands’s president and CEO, said, “While global legalization of cannabis is still in its infancy, we continue to believe the long-term opportunity in this evolving market is substantial.”

Regarding the purchase of additional shares, Canopy’s CEO, David Klein, said, “This additional investment validates the work our team has done since attracting the initial investment in 2017.” Klein adds that it will strengthen Canopy’s ability to pursue the immense market and product opportunities available not only in Canada and the U.S. but also elsewhere.

Most attractive choice

The months ahead are promising for the cannabis sector as a new administration takes over the reins of the U.S. government. President Biden and Vice-President Kamala are likely to tackle federal cannabis reform. In the November 2020 elections, cannabis legalization passed in Arizona, Mississippi, Montana, New Jersey, and South Dakota.

Aphria is now the top-of-mind choice among all weed stocks. The most recent better-than-expected quarterly results and coming merger with rival Tilray are the reasons for the renewed investors’ interest.

The Aphria-Tilray union will produce a cannabis powerhouse in North America. While it’s a takeover by Aphria, the combined businesses will use the Tilray name. A new growth driver is the nearly $300 million acquisition of SweetWater Brewing, a cannabis-flavoured beer maker. Aphria can compete with the Canopy-Constellation Brands tandem.

Aphria’s CEO Irwin Simon said new brands and product innovation would enable the company to outperform market players. Management is laser-focused on profitability as the industry evolves and consumer and patient preferences and demands change.

Operational excellence is also a major focus. Aphria expects to remain a low-cost, high-quality cannabis producer. Its cost-management strategies should increase profitability and result in a strong cash position for growth and expansion of geographic reach. Market analysts are bullish and recommend a buy rating. The forecast is a 58% climb of the current share price to $26 in the next 12 months.

Head start

Canopy Growth and Aphria are not without competition. According to Viridian Capital Advisors, some U.S. cannabis companies are due to close US$975 million new equity raises to fund America’s growing cannabis market. While the two Canadian producers have a head start in 2021, the battle for supremacy should be tough.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Christopher Liew has no position in any of the stocks mentioned.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »